← All trials
NCT06276998
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 12, 2023
- Primary completion
- Aug 4, 2025
- Completion date
- Nov 20, 2026
- First posted
- Feb 26, 2024
- Last posted
- Mar 22, 2024
- Enrollment
- 430
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lynk Pharmaceuticals Co., LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.